Published on
October 27, 2026
- 13:00 GMT
Syncromune Reports Long-Term Data from Phase 1 Study in Metastatic Prostate Cancer with Investigational SYNC-T Therapy ...
50% of patients who achieved a complete response (n=6) remain disease-free more than two years after treatment 80% of patients treated with SYNC-T Therapy SV-102 (n=15) alive at 24 months Median overall survival not reached at nearly 30 months of follow-up …
Distribution channels:
